ALKERMES | ALKS - Cost Of Sales


ALKERMES reported $73.25M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
AbbVie USD 4.22B 329M Mar/2026
Acadia Pharmaceuticals USD 24.79M 1.43M Mar/2026
ALKERMES USD 73.25M 27.04M Mar/2026
Amgen USD 1.6B 187M Mar/2026
Biogen USD 797.5M 302M Mar/2026
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Coherus Biosciences USD 4.04M 324K Dec/2025
Eli Lilly USD 3.58B 205M Mar/2026
Gilead Sciences USD 1.44B 174M Mar/2026
Heron Therapeutics USD 11.12M 795K Dec/2025
Ionis Pharmaceuticals USD 3M 5M Mar/2026
J&J USD 8.07B 103M Mar/2026
Merck USD 2.94B 380M Mar/2026
Minerva Neurosciences 386K 31K Jun/2024
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 13.8M 3.8M Mar/2026
Otsuka Holdings JPY 174.09B 18.65B Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Vertex Pharmaceuticals USD 392.8M 73.2M Mar/2026